scholarly journals The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study

Thyroid ◽  
2016 ◽  
Vol 26 (9) ◽  
pp. 1293-1299 ◽  
Author(s):  
Naoyoshi Onoda ◽  
Kiminori Sugino ◽  
Takuya Higashiyama ◽  
Makoto Kammori ◽  
Kazuhisa Toda ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prospective Study ◽  
Cancer Patients ◽  
Anaplastic Thyroid Cancer ◽  
Weekly Paclitaxel ◽  
Safety And Efficacy

scholarly journals Survival and Surgical Complications in Anaplastic Thyroid Cancer Patients After Completed Multimodal Treatment

2020 ◽  
Vol 40 (12) ◽  
pp. 6979-6985
Author(s):  
BIANCA LORNTZSEN ◽  
ANNE-BIRGITTE JACOBSEN ◽  
KRYSTYNA K. GRØHOLT ◽  
EVA SIGSTAD ◽  
TERJE OSNES
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Surgical Complications ◽  
Multimodal Treatment ◽  
Anaplastic Thyroid Cancer

scholarly journals Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent

Oncotarget ◽  
2016 ◽  
Vol 8 (7) ◽  
pp. 11566-11578 ◽  
Author(s):  
Jikui Guan ◽  
Georg Wolfstetter ◽  
Joachim Siaw ◽  
Damini Chand ◽  
Fredrik Hugosson ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Anaplastic Lymphoma Kinase ◽  
Anaplastic Thyroid Cancer ◽  
Anaplastic Lymphoma

scholarly journals Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

2017 ◽  
Vol 102 (6) ◽  
pp. 1943-1950 ◽  
Author(s):  
Ashish V. Chintakuntlawar ◽  
Kandelaria M. Rumilla ◽  
Carin Y. Smith ◽  
Sarah M. Jenkins ◽  
Robert L. Foote ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Multimodal Therapy ◽  
Anaplastic Thyroid Cancer

Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation

2020 ◽  
Vol 27 (12) ◽  
pp. 685-697
Author(s):  
Kathrin A Schmohl ◽  
Yang Han ◽  
Mariella Tutter ◽  
Nathalie Schwenk ◽  
Rim S J Sarker ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Thyroid Hormones ◽  
Cancer Patients ◽  
Tumour Growth ◽  
Growth Regulation ◽  
Specific Inhibitor ◽  
Integrin Αvβ3 ◽  
Anaplastic Thyroid Cancer

Thyroid hormones are emerging as critical regulators of tumour growth and progression. To assess the contribution of thyroid hormone signalling via integrin αvβ3, expressed on many tumour cells, endothelial cells, and stromal cells, to tumour growth, we compared the effects of thyroid hormones vs tetrac, a specific inhibitor of thyroid hormone action at integrin αvβ3, in two murine xenograft tumour models with and without integrin αvβ3 expression. Integrin αvβ3-positive human anaplastic thyroid cancer cells SW1736 and integrin αvβ3-negative human hepatocellular carcinoma cells HuH7 were injected into the flanks of nude mice. Tumour growth was monitored in euthyroid, hyperthyroid, hypothyroid, and euthyroid tetrac-treated mice. In SW1736 xenografts, hyperthyroidism led to a significantly increased tumour growth resulting in a decreased survival compared to euthyroid mice, while tumour growth was significantly reduced and, hence, survival prolonged in hypothyroid and tetrac-treated mice. Both proliferation and vascularisation, as determined by Ki67 and CD31 immunofluorescence staining, respectively, were significantly increased in tumours from hyperthyroid mice as compared to hypothyroid and tetrac-treated mice. No differences in tumour growth, survival, or Ki67 staining were observed between the different groups in integrin αvβ3-negative HuH7 xenografts. Vascularisation, however, was significantly decreased in hypothyroid and tetrac-treated mice compared to euthyroid and hyperthyroid mice. Apoptosis was not affected in either tumour model, nor were cell proliferation or apoptosis in vitro. Tumour growth regulation by thyroid hormones in αvβ3-positive tumours has important implications for cancer patients, especially those with thyroid dysfunctions and thyroid cancer patients treated with thyrotropin-suppressive L-thyroxine doses.

scholarly journals Anaplastic thyroid carcinoma

2003 ◽  
Vol 50 (3) ◽  
pp. 131-134
Author(s):  
Vladan Zivaljevic ◽  
Aleksandar Diklic ◽  
Ivan Paunovic ◽  
Ksenija Krgovic ◽  
Rastko Zivic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Thyroid Carcinoma ◽  
Cancer Patients ◽  
Anaplastic Thyroid Cancer ◽  
Anaplastic Thyroid Carcinoma ◽  
Endocrine Surgery ◽  
Papillary Thyroid ◽  
Anaplastic Transformation ◽  
Tumor Reduction

The aim of the present paper was to study some characteristics and posibility of surgery of anaplastic thyroid cancer. During five years period in Center for endocrine surgery, we found anaplastic thyroid cancer in 65 patienst (44 female and 21 male), median age 63 years (from 37 to 88 years). Surgical treatment was peerformed in one half (32) anaplastic thyroid cancer patients, at majority of them operative biopsy or tumor reduction only. Radical syrgery was performed in about 10% patients. Posibility of surgery in anaplastic thyroid cancer are very limited. In one third patients there were longstanding goter or thyroid nodul or histological verified dediferentiation of papillary thyroid cancer. This patienst should be operated formerly, before anaplastic transformation.

scholarly journals 1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study

2021 ◽  
Vol 32 ◽  
pp. S1191
Author(s):  
N.M. La Verde ◽  
D. Dalu ◽  
A.L. Ridolfo ◽  
M.S. Cona ◽  
D. De Francesco ◽  
...  
Keyword(s):  
Prospective Study ◽  
Cancer Patients ◽  
Pneumococcal Vaccines ◽  
Active Therapy ◽  
Safety And Efficacy ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document